ReSound® Launches New Wireless Hearing Aid, Bringing Industry-Leading Connectivity and Sound Quality to Wearers Where Budget Matters
30.9.2015 14:30 | Business Wire
ReSound today announced the global launch of the ReSound Enya family of hearing aids, making the company’s industry-leading, innovative hearing technologies accessible to even more people living with hearing loss. For the first time, the company is making its renowned sound expertise and innovative wireless technologies, which were previously reserved to the highest price points, available in lower priced solutions.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150930006212/en/
ReSound Enya (Photo: Business Wire)
ReSound Enya delivers excellent sound quality in discreet, durable models designed to meet the challenges of a rich, active lifestyle. With ReSound Enya, users have access to the category’s best available performance without sacrificing comfort and ease of use.
ReSound is the first in the industry to build advanced connectivity into an affordable device, allowing wearers to:
- Enjoy clear speech and a comfortable listening experience in everyday situations both indoors and out.
- Stream sound from the TV, mobile phone, music player directly to the ReSound Enya hearing aids with ReSound Unite™ wireless accessories.
- Use a smartphone to easily control the hearing aid volume and program settings with the ReSound Control™ app, paired with the ReSound Unite Phone Clip+.
- Get relief from tinnitus with the in-built Tinnitus Sound Generator™.
ReSound also recently introduced ReSound ENZO2™, the world’s most advanced Smart Hearing aid for people with severe-to-profound hearing loss. ReSound ENZO2 builds on the revolutionary capabilities of ReSound LiNX2™, the world’s first full family of Made for iPhone hearing aids. Wearers will experience a vivid sense of space and speech with Spatial Sense™, and have access to direct streaming of sounds to their hearing aids, including music and phone calls. ReSound ENZO2 is easily controlled by the ReSound Smart™ app, providing discreet, on-the-go personalization directly from a user’s smartphone, or from their wrist using the app extension for Apple Watch. ReSound ENZO2 is available to U.S. consumers immediately and coming soon to additional markets around the world.
“We are pleased to be able to offer even more choices for people looking to take control of their hearing loss,” said GN ReSound CEO Anders Hedegaard. “Our dedication to delivering the most advanced hearing solutions also means making these technologies accessible to as many users as possible. Diversifying our portfolio ensures that whether a person is living with mild or severe-to-profound hearing loss, they will be able to find a superior hearing solution that meets their unique needs at the price point that fits their lifestyle. We remain committed to pushing the limits in terms of what is possible for Smart Hearing solutions, and we are proud to offer a complete portfolio of innovative options that truly improve peoples’ lives.”
The ReSound Control app is available for free and compatible with iOS and Android devices. Consumers can find more information about ReSound Enya at www.resound.com/enya. For U.S. consumers and individuals interested in information about ReSound Smart Hearing solutions, including ReSound ENZO2 and the ReSound Smart app, please visit www.resound.com.
About GN ReSound
GN ReSound is a leading international developer and manufacturer of advanced and innovative hearing healthcare solutions. It advances the wireless revolution with its unique 2.4 GHz and Bluetooth® Smart solutions. GN ReSound has reinvented the hearing system with its revolutionary ReSound LiNX2 hearing aids, and is driving and defining the future of hearing care. The company demonstrates its commitment to making life sound better through its research, insights and expertise in sound.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
IFF to Present at the Barclays Global Consumer Staples Conference21.8.2017 20:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, today announced that Andreas Fibig, Chairman and Chief Executive Officer will present at the Barclays Global Consumer Staples Conference in Boston, MA on Thursday, September 7, 2017 at 11:15 a.m. EDT. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for explorati
Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform21.8.2017 20:11 | Pressemelding
Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including: Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets Proprietary allogeneic (“readily accessible”) immunotherapy platform 200+ issued and pending patents in cell therapy
European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25 | Pressemelding
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the
IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00 | Pressemelding
IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman
PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03 | Pressemelding
PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate
Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 08:00 | Pressemelding
Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom